Virbac UK Veterinary
Caution, This content is for veterinary professionals.

Virbagen® Omega

Parvovirus need not be a death sentence

Virbagen® Omega contains recombinant interferon omega of feline origin. Type I interferons are cytokines that act as protein messengers which induce multiple immune pathways in the cell. These include the increased production of potent anti-viral proteins and enzymes. Licensed to treat Canine Parvovirus, Virbagen® Omega is administered intravenously and is proven to decrease mortality rate when used in conjunction with supportive therapies.

Product Features & Benefits: 

  • Licensed for the treatment of parvovirus in dogs

  • Mortality in dogs is reduced by 4.4x when using Virbagen® Omega in combination with supportive therapy rather than supportive therapy alone.1

  • When looking specifically at an unvaccinated population, the use of Virbagen® Omega decreases mortality by 6.4 times

  • Reduces clinical signs of parvovirus to facilitate a quicker recovery1

  • The canine dose 2.5 MU/Kg IV once daily for 3 days.Use in a 10kg dog would require 25MU per day and therefore 75MU for the course.  One vial of reconstituted Virbagen® Omega contains 10MU of interferon,which would result in 2.5 vials per day for this example

  • Licensed, also, to treat FeLV and FIV/FeLV co-infected cats where it is proven to:

    • Significantly reduce the clinical signs 

    • Decrease overall mortality rate 

    • Improve overall quality of life 

  • In cats, Virbagen® Omega should be injected subcutaneously once daily for five consecutive days, at a dose rate of 1 MU/kg bodyweight, starting on days 0, 14 and 60.

 

Presentations Available: 

Available in 2 and 5 vial packs.

 

1. K. De Mari et al. Treatment of canine parvovirus enteritis with interferon-omega in a placebo-controlled field trial, Veterinary Record (2003) 152, 105-108.

Resources

Caution, This content is for veterinary professionals. Login to access the content.